Literature DB >> 18372499

Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure.

L Golden-Mason1, L Madrigal-Estebas, E McGrath, M J Conroy, E J Ryan, J E Hegarty, C O'Farrelly, D G Doherty.   

Abstract

BACKGROUND: Natural killer (NK) cells may be impaired in patients with persistent hepatitis C virus (HCV) infection, but studies to date have yielded inconsistent findings due to patient and virus heterogeneity and difficulties obtaining appropriate controls. AIMS: To overcome these variables, we have examined numbers, phenotypes, cytotoxic activities and cytokine profiles of circulating NK cells from Irish women who acquired infection through administration of HCV genotype 1b-contaminated anti-D immunoglobulin from a single source and matched controls.
RESULTS: Comparing 29 women who developed persistent infection with 21 who spontaneously resolved infection and 26 controls, we found that NK cell numbers were consistently lower in the persistently infected group (p = 0.02 and 0.002). This decrease was due to depletions of NK cells expressing low levels of CD56 (CD56(dim) NK cells; p = 0.004 and 0.0001), whilst CD56(bright) NK cells were expanded (p = 0.004 and 0.0001). Compared to HCV resolvers, CD56(dim) NK cells from persistently infected patients less frequently expressed CD16 and more frequently expressed NKG2A/C/E. These phenotypic changes did not significantly affect natural or interleukin-2-induced cytotoxicity by peripheral blood mononuclear cells against K562 and Daudi targets. Greater frequencies of CD56(bright) NK cells from chronic HCV patients produced interferon-gamma compared with HCV responders (p = 0.05) and controls (p = 0.0001) after phorbol ester stimulation in vitro.
CONCLUSIONS: Alterations in NK subset distributions in chronic HCV infection may explain why previous reports of impaired NK cell functions were difficult to confirm. Altered NK cell functions may contribute to impaired cellular immune responses and chronicity of disease following HCV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18372499     DOI: 10.1136/gut.2007.130963

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  66 in total

1.  Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells.

Authors:  Joo Chun Yoon; Jong-Baeck Lim; Jeon Han Park; Jae Myun Lee
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 2.  Natural killer cells in immunodefense against infective agents.

Authors:  Nicolas Zucchini; Karine Crozat; Thomas Baranek; Scott H Robbins; Marcus Altfeld; Marc Dalod
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

Review 3.  CD56bright natural killer (NK) cells: an important NK cell subset.

Authors:  Aurélie Poli; Tatiana Michel; Maud Thérésine; Emmanuel Andrès; François Hentges; Jacques Zimmer
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

4.  Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.

Authors:  L Long; M Jia; X Fan; H Liang; J Wang; L Zhu; Z Xie; T Shen
Journal:  Clin Exp Immunol       Date:  2017-04-07       Impact factor: 4.330

5.  Activation of natural killer cells during acute infection with hepatitis C virus.

Authors:  Barbara Amadei; Simona Urbani; Angelica Cazaly; Paola Fisicaro; Alessandro Zerbini; Parvin Ahmed; Gabriele Missale; Carlo Ferrari; Salim I Khakoo
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

6.  The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response.

Authors:  Christopher R Bolen; Michael D Robek; Leonid Brodsky; Vincent Schulz; Joseph K Lim; Milton W Taylor; Steven H Kleinstein
Journal:  J Interferon Cytokine Res       Date:  2012-10-15       Impact factor: 2.607

Review 7.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 8.  A new insight into hepatitis C vaccine development.

Authors:  Chun I Yu; Bor-Luen Chiang
Journal:  J Biomed Biotechnol       Date:  2010-06-13

9.  Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines.

Authors:  Damien Sène; Franck Levasseur; Michal Abel; Marion Lambert; Xavier Camous; Céline Hernandez; Véronique Pène; Arielle R Rosenberg; Evelyne Jouvin-Marche; Patrice N Marche; Patrice Cacoub; Sophie Caillat-Zucman
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

10.  Innate immune function in placenta and cord blood of hepatitis C--seropositive mother-infant dyads.

Authors:  Christine Waasdorp Hurtado; Lucy Golden-Mason; Megan Brocato; Mona Krull; Michael R Narkewicz; Hugo R Rosen
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.